Copy to clipboard 
FDA has cleared more than 2,500 devices between 2021 and 2025, with spine outpacing the other major segments in orthopedics for the most clearances over the five-year span, driven in recent years by advances made by smaller companies like SI-BONE, Centinel Spine and Carlsmed. Their successes show that niche spine subsegments, such as SI fusion solutions, carry significant upside.
Although foot and ankle continues to grow in the high single digits, procedure volumes remain stagnant. Case volumes began to decline in late 2023 and remained inconsistent throughout 2024 and into early 2025. Companies in the space are hopeful that foot and ankle will return to strong growth this year. In the meantime, companies are developing new solutions for core trauma, which is providing a runway for growth.
